3v35: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Aldose reductase complexed with a nitro compound== | ==Aldose reductase complexed with a nitro compound== | ||
<StructureSection load='3v35' size='340' side='right' caption='[[3v35]], [[Resolution|resolution]] 1.90Å' scene=''> | <StructureSection load='3v35' size='340' side='right'caption='[[3v35]], [[Resolution|resolution]] 1.90Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3v35]] is a 1 chain structure with sequence from [ | <table><tr><td colspan='2'>[[3v35]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3V35 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3V35 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=DMF:DIMETHYLFORMAMIDE'>DMF</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=NTI:2-[(5-NITRO-1,3-THIAZOL-2-YL)CARBAMOYL]PHENYL+ACETATE'>NTI</scene | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.9Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DMF:DIMETHYLFORMAMIDE'>DMF</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=NTI:2-[(5-NITRO-1,3-THIAZOL-2-YL)CARBAMOYL]PHENYL+ACETATE'>NTI</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3v35 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3v35 OCA], [https://pdbe.org/3v35 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3v35 RCSB], [https://www.ebi.ac.uk/pdbsum/3v35 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3v35 ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/ALDR_HUMAN ALDR_HUMAN] Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies. | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 23: | Line 21: | ||
==See Also== | ==See Also== | ||
*[[Aldose | *[[Aldose reductase 3D structures|Aldose reductase 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: Chen | [[Category: Chen Y]] | ||
[[Category: Hu | [[Category: Hu X]] | ||
[[Category: Luo | [[Category: Luo H]] | ||
[[Category: Zhang | [[Category: Zhang L]] | ||
[[Category: Zheng | [[Category: Zheng X]] | ||
Latest revision as of 15:16, 8 November 2023
Aldose reductase complexed with a nitro compoundAldose reductase complexed with a nitro compound
Structural highlights
FunctionALDR_HUMAN Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies. Publication Abstract from PubMedA little is more than enough: Aldose reductase (AR) is a potential target in a wide range of diseases but its utility may be limited by the side effects caused by complete inhibition. Furthermore, known inhibitors of AR have suffered in clinical evaluation due to poor bioavailability. Here, the clinically used antiprotozoal drug nitazoxanide with proven bioavailability has been shown to partially inhibit AR, potentially circumventing the negatives effects of complete enzyme inhibition. Partial Inhibition of Aldose Reductase by Nitazoxanide and Its Molecular Basis.,Zheng X, Zhang L, Chen W, Chen Y, Xie W, Hu X ChemMedChem. 2012 Aug 13. doi: 10.1002/cmdc.201200333. PMID:22890894[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||